Clinical Research Directory

Inclusion Criteria: * Men and women aged 18-\<70 years of all race/ethnicity groups * CKD stage 3 (eGFR \>30 to 59 ml/min/1.73m2) * uACR ≥ 200 mg/g * CAC Agatston score ≥30 * Hypertension, diabetes, dyslipidemia, or established ASCVD (CAD, ischemic stroke, and peripheral artery disease), defined by self-report, ICD-10 codes, or the use of medications for these conditions. * Ability to provide informed consent. Exclusion Criteria: * Current colchicine therapy * Hepatic disease * Any clinically active diagnosed infection requiring systemic antimicrobial therapy, positive microbiologic evidence of infection, or infection-related hospitalization within 30 days prior to study enrollment. * Immunosuppression * Current use of chemotherapy drugs or active cancer * Pregnancy/breastfeeding * Hospitalized within the past 6 months * Allergic/intolerance to colchicine * Use of p-gp inhibitor ( such as Verapamil, Quinidine, Amiodarone, Ritonavir, Lopinavir/ritonavir, Saquinavir, Nelfinavir) * Use of strong CYP3A4 inhibitors (such as Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Clarithromycin, Erythromycin) * HIV infection * Gout attack ≥ 1 time per year * Severe anemia (hemoglobin \< 8 g/dl for women and \< 9 g/dl for men) * eGFR \<30 ml/min/1.73m2 * uACR \<200 mg/g * WBC \<3.0 x109/L * AST or ALT \> 3 x Upper Limit of Normal (ULN) * Total bilirubin \>2 x ULN * Glucose \>300mg/dl * Uses nicotine products or other recreational drugs * Unable to read or speak English * Participant in other conflict clinical trial, * Unable to complete the study measurements * Unable to undergo to CT or DXA scans * Unsafe to participate in this study per investigator's judgement.